Calliditas Therapeutics AB aims to have a US NASDAQ listing in time for a scheduled Phase III readout assessing its lead asset as a first-in-class treatment for inflammatory renal disease IgA nephropathy (IgAN), an orphan chronic autoimmune disease, the Swedish specialty pharma’s CEO told Scrip.
Renee Aguiar Lucander also said Calliditas expected to file for accelerated or conditional approval in the US and Europe later this year based on the ongoing Phase III efficacy study evaluating Nefecon (targeted-release